Jennifer Veneris

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study

Ana Oaknin, Lucy Gilbert, Anna V. Tinker et al. · Journal for ImmunoTherapy of Cancer · 2022 · 322 citations · Full text

Medicine, Oncology, Pharmacology +15

Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma

Joyce F. Liu, Niya Xiong, Susana M. Campos et al. · Journal of Clinical Oncology · 2021 · 195 citations

Medicine, Oncology, Pharmacology +17

Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers

Joyce F. Liu, Michael S. Gordon, Jennifer Veneris et al. · Gynecologic Oncology · 2019 · 137 citations

Medicine, Oncology, Pharmacology +14

Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors

Thierry André, Dominique Berton, Giuseppe Curigliano et al. · JAMA Network Open · 2023 · 120 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +14

Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study

Ana Oaknin, Bhavana Pothuri, Lucy Gilbert et al. · Clinical Cancer Research · 2023 · 81 citations · Full text

Medicine, Gynecology, Oncology +17